GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aceragen Inc (STU:V9Z) » Definitions » Institutional Ownership

Aceragen (STU:V9Z) Institutional Ownership : 0.42% (As of Jun. 06, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Aceragen Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Aceragen's institutional ownership is 0.42%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Aceragen's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Aceragen's Float Percentage Of Total Shares Outstanding is 0.00%.


Aceragen Institutional Ownership Historical Data

The historical data trend for Aceragen's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aceragen Institutional Ownership Chart

Aceragen Historical Data

The historical data trend for Aceragen can be seen below:

2023-03-31 2023-04-30 2023-05-31 2023-06-30 2023-07-31 2023-08-31 2023-09-30 2023-10-31 2023-11-30 2023-12-31
Institutional Ownership 2.28 2.28 2.14 1.78 1.77 0.97 0.77 0.37 0.37 0.42

Aceragen Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.


Aceragen (STU:V9Z) Business Description

Traded in Other Exchanges
N/A
Address
505 Eagleview Boulevard, Suite 212, Exton, PA, USA, 19341
Aceragen Inc is a clinical-stage biopharmaceutical company committed to transforming the care of people living with rare pulmonary and rheumatic diseases. The company portfolio includes late-stage programs based on well-established biological principles that are developing to be inventive therapeutics capable of addressing the unmet medical needs of individuals living with rare diseases.

Aceragen (STU:V9Z) Headlines

No Headlines